Clinical Trials on Dyslipidemia in Ireland

Total 94 results

GlaxoSmithKline

Completed

Dyslipidemia Study Investigating The Increase In "Good Cholesterol"

Dyslipidaemias

United States, Canada
NeuroBo Pharmaceuticals Inc.

Completed

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia (INDIGO-1)

Severe Hypertriglyceridemia | Mixed Dyslipidaemia

United States, Canada
Kowa Research Institute, Inc.

Completed

Prevail-Us: A Study Of Pitavastatin 4 mg Vs. Pravastatin 40 mg In Patients With Primary Hyperlipidemia Or Mixed Dyslipidemia (PREVAIL-US)

Mixed Dyslipidemia | Primary Dyslipidemia

United States
Abbott

Completed

An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME) (SUPREME)

Hyperlipidemia | Mixed Dyslipidemia

United States
Sanofi

Terminated

European Trial About Effect of RimoNabant on Abdominal Obese Patients With dysLipidemia (ETERNAL)

Obesity | Dyslipidemias

Germany, Netherlands, Turkey, Slovakia, United Kingdom, Finland, Hungary, Ireland, Italy, Norway, Greece, Sweden, Czech Republic, Portugal, Switzerland
Solvay Pharmaceuticals

Terminated

Fenofibrate and Metformin Insulin Sensitivity in Type 2 Diabetics Study

Type 2 Diabetes | Dyslipidemia

Finland, Ireland, Italy
Bristol-Myers Squibb

Completed

Safety Study of BMS-770767 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, Australia, United States
Takeda

Completed

Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol

Dyslipidemia

United States
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia

Dyslipidemia

United States, Canada
Pfizer

Completed

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Arrowhead Pharmaceuticals

Active, not recruiting

Study of ARO-APOC3 in Adults With Dyslipidemia

Dyslipidemias

United States, Australia, Canada, Poland, Netherlands, New Zealand, Hungary
Pfizer

Completed

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Dyslipidemia | Hypercholesterolemia

United States, Canada
Amgen

Completed

Open-label Extension Study of Evolocumab (AMG 145) in Adults With Hyperlipidemia and Mixed Dyslipidemia (OSLER-2)

Hyperlipidemia and Mixed Dyslipidemia

United States, Canada, Denmark, France, Italy, Belgium, Czechia, Taiwan, Japan, Switzerland, Germany, United Kingdom, Korea, Republic of, Hong Kong, Netherlands, New Zealand, South Africa, Australia, Spain, Austria, Hungary, Russian... and more
Providence VA Medical Center
Sandra A. Daugherty Foundation

Completed

Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes

Hypertension | Diabetes | Dyslipidemia

United States
Amgen

Completed

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

Dyslipidemia

United States, Belgium, Denmark, Finland, France, Italy, Spain, Hungary, Poland, Germany, Czechia, Turkey, United Kingdom, Malaysia, Australia, Hong Kong, New Zealand, Canada, South Africa, Greece, Portugal, Netherlands, Russian Federation and more
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER)

Dyslipidemia

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, Czechia, Hungary, Taiwan, Colombia, Poland, Russian Federation, Switzerland, Korea, Republic of, Mexico, ... and more
Amgen

Completed

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension (FOURIER OLE)

Dyslipidemia

United States, Poland, Czechia, Hungary, Russian Federation, Ukraine, Slovakia
Pfizer

Completed

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events (SPIRE-LDL)

Hyperlipidemia

United States, Spain, Taiwan, United Kingdom, Canada, Mexico, France, Hungary, Lithuania, Colombia, Romania, Russian Federation
Pfizer

Terminated

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

Dyslipidemia | Hypercholesterolemia | Hyperlipidemia

United States
Pfizer

Terminated

A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.

Dyslipidemia | Hyperlipidemia

United States
Pfizer

Completed

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.

Dyslipidemia | Hypercholesterolemia | Hyperlipidemia

United States
Kowa Research Institute, Inc.

Withdrawn

Efficacy & Long-term Safety Comparison Study of NK-104-CR & Livalo® IR With Primary Hyperlipidemia or Mixed Dyslipidemia

Dyslipidemia | Hyperlipidemia

United States
Abbott

Completed

Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia (ASA EFFECTS)

Dyslipidemia

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia (JEWEL I)

Hypertension | Dyslipidemia

Canada, United Kingdom
BIO-CAT Inc.
Atlantia Food Clinical Trials; Cork University Hospital

Completed

Effect of Candida Rugosa Lipase on Serum Triglyceride Lowering

Hypertriglyceridemia

Ireland
Amgen

Completed

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

Dyslipidemia | Medical Conditions to be Studied | ASCVD Management

United States
Providence VA Medical Center
Rhode Island Foundation

Completed

Combined Behavioral and Pharmacological Intervention for Cardiovascular Risk Reduction in Diabetic Patients

Hypertension | Diabetes | Dyslipidemia | Coronary Arteriosclerosis

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk (TOGETHER)

Hypertension | Dyslipidemia

United States
PepsiCo Global R&D

Completed

The Effect of Oats Containing 1.4g Beta Glucan on Fecal Bacterial Population(s) and Plasma Cholesterol in Healthy Adults With Elevated Cholesterol Levels

Microbiome | Plasma Cholesterol | Prebiotic

Ireland
Providence VA Medical Center
Merck Sharp & Dohme LLC

Completed

Strategies to Maintain Cardiac Risk Control After Discharge From Cardiovascular Risk Reduction Clinic

Hypertension | Diabetes | Dyslipidemia | Coronary Atherosclerosis

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia. (JEWEL II)

Hypertension | Hyperlipidemia

Greece, Austria, Finland, Italy, Hungary, Belgium, Spain, Ireland, Portugal, Slovenia, Switzerland
Queen's University, Belfast
Belfast Health and Social Care Trust

Recruiting

Determining the Lipid Lowering Effect of Fenugreek Seed Tea

Hyperlipidemias

United Kingdom
Amgen

Completed

Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia (BANTING)

Type 2 Diabetes | Hypercholesterolemia | Mixed Dyslipidemia

United States, Italy, Belgium, Spain, Canada, Poland, Mexico
Abbott

Completed

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

Dyslipidemias | Coronary Heart Disease | Mixed Dyslipidemia | Combined (Atherogenic) Dyslipidemia

United States
Sunnybrook Health Sciences Centre
Merck Frosst Canada Ltd.; Schering-Plough

Terminated

INdians Followed for INtensive Lipid Lowering Treatment and Its safetY (INFINITY)

Hypercholesterolemia

Canada
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Completed

Treatment of High and Very High riSk Dyslipidemic pAtients for the PreveNTion of CardiOvasculaR Events (SANTORINI)

Cardiovascular Diseases | Dyslipidemia | Hypercholesterolemia | Atherosclerotic Cardiovascular Disease

Finland, Netherlands, Spain, Belgium, Sweden, Austria, United Kingdom, Switzerland, Denmark, France, Germany, Portugal, Italy, Ireland
Kowa Research Institute, Inc.
Brigham and Women's Hospital

Terminated

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT) (PROMINENT)

Dyslipidemia | Type2 Diabetes

United States, Spain, Canada, Hungary, Netherlands, Brazil, Bulgaria, Poland, Israel, Russian Federation, Ukraine, Denmark, Czechia, South Africa, Argentina, Mexico, United Kingdom, Romania, Germany, India, Slovakia, Japan, Colombia, ... and more
Takeda
Eli Lilly and Company

Completed

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

Diabetes Mellitus

United States
AstraZeneca

Completed

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

Dyslipidemia | Kidney Disease

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease

Cardiovascular Disease, Coronary Heart Disease, Dyslipidemia, Peripheral Arterial Disease (PAD)

China, United States, Spain, Netherlands, Canada, France, Mexico, Poland, Hungary, Australia, Denmark, United Kingdom, Czech Republic
Brown University
Johns Hopkins University; National Institute on Aging (NIA); Tufts Medical Center and other collaborators

Completed

Pharmacy Home Adherence Reporting and Monitoring Outcomes Study (PHARxMOS)

Hypertension | Diabetes | Hypercholesterolemia

United States
The Miriam Hospital
Merck Sharp & Dohme LLC; Tufts Medical Center

Completed

Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy

HIV Infections | HIV | Hypertriglyceridemia | Hyperlipidemia

United States
Memorial Hospital of Rhode Island
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Translating ATP III Cholesterol Management Guidelines Into Primary Care Practice

Coronary Disease | Hypercholesterolemia | Primary Health Care | Management, Risk

United States
Valbiotis
Institut Pasteur de Lille; Biofortis Mérieux NutriSciences

Completed

Effect of Totum-63, Active Ingredient of Valedia, on Glucose and Lipid Homeostasis on Subjects With Prediabetes (TOTUM-63 TWO)

Obesity | Disease | Insulin Resistance | Type 2 Diabetes | Hypertriglyceridemia | Prediabetes

France, Ireland, Serbia, Slovenia
National Institute of Allergy and Infectious Diseases...

Completed

The Effect of Fish Oil Plus Fenofibrate on Triglyceride Levels in People Taking Highly Active Antiretroviral Therapy (HAART)

HIV Infections | Hypertriglyceridemia

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST 2)

Diabetes Mellitus, Type 2 | Dyslipidemia | Peripheral Vascular Disease | Coronary Arteriosclerosis | Cerebrovascular Accident

Greece, Ireland, Russian Federation, Slovakia, Poland, Hungary, Portugal, Switzerland
GlaxoSmithKline

Completed

Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects

Hypertriglyceridemia

United States
Eli Lilly and Company

Terminated

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol (ACCENTUATE)

Hyperlipidemia

United States, Puerto Rico
GlaxoSmithKline

Completed

A Second Open-Label Extension of a Double-Blind, Parallel, Phase IV Study to Assess the Efficacy and Safety of Adjunctive Lovaza® (Formerly Known as Omacor®) Therapy in Hypertriglyceridemic Subjects Treated With Antara™

Hypertriglyceridemia

United States
Amgen

Completed

Open-label Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab

Hypercholesterolemia

Canada, Netherlands, Spain, Belgium, United States, Russian Federation, Czechia, Mexico, Korea, Republic of, Australia, United Kingdom, Argentina, Israel, France, Hungary, Germany, Greece, Poland, Switzerland, Italy, Brazil, Sweden, Norwa... and more

Clinical Trials on Dyslipidemia in Ireland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Panama

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations